Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIV-573 placebo-controlled phase 2 study in moderate to severe atopic dermatitis
2026-526485-25-00Phase 2Authorised
- Sponsor
- Triveni Bio
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing TRIV-573 with Placebo (2 arms). Primary endpoint: Percentage of participants with improvement of atopic dermatitis. Planned start Oct 2026; status: authorised.
02
Drugs
TRIV-573
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2026-526485-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526485-25-00.